Financial reports
10-Q
2024 Q1
Quarterly report
6 May 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K/A
2022 FY
Annual report (amended)
24 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
6 May 24
8-K
Departure of Directors or Certain Officers
16 Apr 24
8-K
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
28 Mar 24
8-K
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop a Novel Therapeutic for Obesity Management
5 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
11 Dec 23
8-K
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
9 Nov 23
8-K
Other Events
26 Sep 23
8-K
Entry into a Material Definitive Agreement
22 Sep 23
8-K
Departure of Directors or Certain Officers
29 Aug 23
8-K
Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
3 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
3 Aug 23
424B5
Prospectus supplement for primary offering
23 Feb 23
S-3
Shelf registration
8 Nov 22
S-8
Registration of securities for employees
2 Aug 21
424B4
Prospectus supplement with pricing info
2 Aug 21
8-A12B
Registration of securities on exchange
26 Jul 21
S-1/A
IPO registration (amended)
26 Jul 21
S-1
IPO registration
9 Jul 21
DRS/A
Draft registration statement (amended)
2 Jul 21
DRS/A
Draft registration statement (amended)
22 Jun 21
Proxies
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
Other
EFFECT
Notice of effectiveness
21 Nov 22
CORRESP
Correspondence with SEC
16 Nov 22
UPLOAD
Letter from SEC
15 Nov 22
EFFECT
Notice of effectiveness
30 Jul 21
CERT
Certification of approval for exchange listing
29 Jul 21
SEC STAFF
SEC staff action: Order
29 Jul 21
CORRESP
Correspondence with SEC
27 Jul 21
CORRESP
Correspondence with SEC
27 Jul 21
SEC STAFF
SEC staff action: Order
21 Jul 21
CORRESP
Correspondence with SEC
19 Jul 21